Loading...
•
Dec 31, 2025
CRISPR Therapeutics Q4 2025 Earnings Report
CRISPR Therapeutics reported fourth quarter 2025 CASGEVY revenue growth and higher operating expenses, resulting in a wider net loss year-over-year.
Key Takeaways
For Q4 2025, CRISPR Therapeutics generated total revenue of 864000, primarily from grant revenue, and reported a net loss of 130613000, or -1.37 per share. R&D expenses increased to 83526000 and collaboration expense rose significantly to 53703000.
Total Q4 revenue was 864000, compared to 35691000 in Q4 2024.
Net loss widened to 130613000, or -1.37 per share.
R&D expenses increased to 83526000 from 71738000 year-over-year.
Cash, cash equivalents, and marketable securities totaled 1975828000 at year end.
Revenue by Segment
Forward Guidance
Management highlighted continued commercial momentum for CASGEVY and advancement of a diversified pipeline, while emphasizing strong liquidity to support operations.
Positive Outlook
- CASGEVY generated 54000000 in Q4 2025 revenue.
- 64 patients received CASGEVY infusions during 2025.
- Cash, cash equivalents and marketable securities of 1975828000 provide strong runway.
- Advancing multiple in vivo and siRNA programs.
- Expanding global reimbursement access for CASGEVY.
Challenges Ahead
- Net loss of 130613000 in Q4 2025.
- Collaboration expense increased significantly year-over-year.
- High R&D spend reflecting pipeline expansion.
- Operating loss of 154764000 in the quarter.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...